Guardant Health, Inc. (GH) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Guardant Health’s revenue went from $25M in fiscal 2016 to $982M in fiscal 2025, growth of about 50.2% a year.
Net income in fiscal 2025 was -$416M, a net margin of -42.4%; the best year in this period was 2016 with -$46M.
Over the twelve months to September 30, 2026, revenue was $1.3B and net income -$485M.
Free cash flow was -$233M in fiscal 2025 and positive in 0 of the 10 years shown.
The diluted share count rose 860% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3B | $982M | $739M | $564M | $450M | $374M | $287M | $214M | $91M | $50M | $25M |
| Gross profit | $834M | $633M | $449M | $337M | — | — | — | — | — | — | — |
| Operating income | -$504M | -$437M | -$444M | -$565M | -$544M | -$411M | -$255M | -$82M | -$93M | -$77M | -$44M |
| Net income | -$485M | -$416M | -$436M | -$479M | -$655M | -$385M | -$254M | -$76M | -$85M | -$83M | -$46M |
| EPS (diluted) | $-3.68 | $-3.32 | $-3.56 | $-4.28 | $-6.41 | $-4.00 | $-2.60 | $-0.84 | $-2.80 | $-7.07 | $-3.53 |
| R&D | $387M | $364M | $348M | $367M | $374M | $263M | $150M | $86M | $51M | $26M | $11M |
| Revenue growth | — | +32.9% | +31.0% | +25.4% | +20.3% | +30.3% | +33.8% | +136.5% | +81.8% | +97.4% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$173M | -$185M | -$240M | -$325M | -$309M | -$209M | -$104M | -$47M | -$72M | -$72M | -$37M |
| Capital spending | -$59M | -$48M | -$35M | -$20M | -$77M | -$75M | -$36M | -$19M | -$20M | -$7M | -$2M |
| Free cash flow | -$232M | -$233M | -$275M | -$345M | -$387M | -$284M | -$140M | -$66M | -$92M | -$79M | -$38M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — |
| Buybacks | $0 | $45M | $0 | $0 | — | — | $0 | $0 | $172000 | $7M | $100000 |
| Stock-based pay | $211M | $166M | $140M | $91M | $95M | $151M | $144M | $17M | $7M | $4M | $2M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $1.2B | $840M | $1.2B | $1.0B | $933M | $1.8B | $523M | $419M | $221M | $34M |
| Debt | — | $1.7B | $1.3B | $1.4B | $1.4B | $1.4B | $854M | $40M | $22M | — | — |
| Equity | — | -$99M | -$140M | $159M | $60M | $645M | $1.3B | $798M | $483M | $309M | $80M |
| Total assets | — | $2.0B | $1.5B | $1.8B | $1.6B | $2.2B | $2.3B | $963M | $587M | $343M | — |
| Shares (diluted) | 134M | 125M | 123M | 112M | 102M | 101M | 98M | 91M | 30M | 13M | 13M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 65.2% | 64.5% | 60.8% | 59.7% | — | — | — | — | — | — | — |
| Operating margin | -39.4% | -44.5% | -60.0% | -100.1% | -121.1% | -110.0% | -88.9% | -38.4% | -102.5% | -153.7% | -173.7% |
| Net margin | -37.9% | -42.4% | -59.1% | -85.0% | -145.6% | -103.0% | -88.5% | -35.3% | -93.8% | -167.0% | -182.7% |
| FCF margin | -18.2% | -23.7% | -37.2% | -61.3% | -86.1% | -76.0% | -48.9% | -30.7% | -101.9% | -158.3% | -152.4% |
| ROIC | — | -27.1% | -29.3% | -29.5% | -30.1% | -16.1% | -9.3% | -9.6% | -14.5% | -19.6% | -43.5% |
| ROE | — | 419.2% | 312.5% | -302.1% | -1087.7% | -59.7% | -19.5% | -9.5% | -17.6% | -27.0% | -57.9% |
Frequently asked questions
What is Guardant Health’s annual revenue?
$982M in fiscal 2025 and $1.3B over the twelve months to September 30, 2026.
How much profit does Guardant Health make?
Net income was -$416M in fiscal 2025 (net margin -42.4%).
Is Guardant Health’s revenue growing?
Yes: revenue rose 32.9% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.